Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04TPU
|
|||
| Former ID |
DIB014744
|
|||
| Drug Name |
RO-5323441
|
|||
| Synonyms |
Placental growth factor inhibitors (humanized mAb, cancer), BioInvent/Thrombogenics/Roche; 89Zr-RO-5323441
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Company |
F Hoffmann-La Roche Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Placenta growth factor (PlGF) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| PI3K-Akt signaling pathway | ||||
| Focal adhesion | ||||
| Pathways in cancer | ||||
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | ||||
| Metabolic pathways | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathway Interaction Database | VEGFR1 specific signals | |||
| Reactome | VEGF ligand-receptor interactions | |||
| VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Focal Adhesion | |||
| Signaling by VEGF | ||||
| Diurnally Regulated Genes with Circadian Orthologs | ||||
| Post-translational modification: synthesis of GPI-anchored proteins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01622764) 89Zr-RO5323441 PET Imaging in Glioblastoma. U.S. National Institutes of Health. | |||
| REF 2 | RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.